Winrevair®

Přípravek Winrevair® je indikován k léčbě plicní arteriální hypertenze (PAH) v kombinaci s jinými terapiemi PAH u dospělých pacientů s funkční třídou dle WHO (WHO FC) II, III a IV.12

SPC Winrevair® k dispozici zde ZIP Winrevair® k dispozici zde

REFERENCE:

1. Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478-1490.
2. Treposuvi. Summary of Product Characteristics. AOP Orphan Ltd; 2023.
3. Adempas. Summary of Product Characteristics. Bayer AG; 2023.
4. Ventavis. Summary of Product Characteristics. Bayer AG; 2023.
5. Adcirca. Summary of Product Characteristics. Eli Lilly Nederland BV; 2023.
6. Volibris. Summary of Product Characteristics. GlaxoSmithKline (Ireland) Limited; 2021.
7. Opsumit. Summary of Product Characteristics. Janssen-Cilag International NV; 2023.
8. Tracleer. Summary of Product Characteristics. Janssen-Cilag International NV; 2023.
9. Uptravi. Summary of Product Characteristics. Janssen-Cilag International NV; 2022.
10. Flolan. Summary of product characteristics, labelling and package leaflet. EMA; 2012.
11. Revatio. Summary of Product Characteristics. Upjohn EESV; 2023.
12. SPC Winrevair®, 7. 5. 2026

Úhradové podmínky >